Recursion Pharmaceuticals Inc's financial performance has deteriorated significantly, with revenue growth declining by 32.98% in Q3 2025 after a strong growth of 30.14% in Q2 2025. Profitability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback